Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FDEQ9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,752
Award facts
- Contract value 100% obligated
- $49,752.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $49,752.39 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award, issued on January 28, 2026, carries an ultimate completion date of February 19, 2026, and includes no set-aside designation, indicating the company competed successfully in unrestricted federal procurement. DMS Pharmaceutical Group is performing at its headquarters location in Park Ridge, Illinois, and will deliver this specialty pharmaceutical product to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The PPV-G GEN V represents a $30.3 billion strategic acquisition vehicle designed to provide DoD healthcare facilities worldwide with comprehensive pharmaceutical supplies, including branded and generic prescription medications, biologics, and medical consumables. The underlying IDC, awarded in November 2025 with a $499,999,999 ceiling value through December 31, 2036, positions DMS Pharmaceutical Group as a critical regional prime vendor contractor capable of fulfilling specialized pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDEQ9?
SPE2DR26FDEQ9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FDEQ9 worth?
The government has obligated $49,752 on SPE2DR26FDEQ9.
Is contract SPE2DR26FDEQ9 an order under another contract?
Yes. SPE2DR26FDEQ9 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEQ9 competed?
The extent of competition for SPE2DR26FDEQ9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award